EA038966B1 - Лентивирусный вектор для генной терапии, способ его получения и его применение - Google Patents
Лентивирусный вектор для генной терапии, способ его получения и его применение Download PDFInfo
- Publication number
- EA038966B1 EA038966B1 EA201692361A EA201692361A EA038966B1 EA 038966 B1 EA038966 B1 EA 038966B1 EA 201692361 A EA201692361 A EA 201692361A EA 201692361 A EA201692361 A EA 201692361A EA 038966 B1 EA038966 B1 EA 038966B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- expression
- siv
- vector
- cells
- a1at
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 230
- 238000000034 method Methods 0.000 title claims abstract description 55
- 238000001415 gene therapy Methods 0.000 title claims abstract description 29
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 115
- 108700019146 Transgenes Proteins 0.000 claims abstract description 113
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 62
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims abstract description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 46
- 201000010099 disease Diseases 0.000 claims abstract description 40
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 230000000241 respiratory effect Effects 0.000 claims abstract description 13
- 239000013612 plasmid Substances 0.000 claims description 95
- 210000004027 cell Anatomy 0.000 claims description 93
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 63
- 108010054218 Factor VIII Proteins 0.000 claims description 63
- 102000001690 Factor VIII Human genes 0.000 claims description 61
- 229960000301 factor viii Drugs 0.000 claims description 60
- 230000001225 therapeutic effect Effects 0.000 claims description 59
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 46
- 241000713666 Lentivirus Species 0.000 claims description 24
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 20
- 230000007812 deficiency Effects 0.000 claims description 19
- 238000001890 transfection Methods 0.000 claims description 14
- 208000009292 Hemophilia A Diseases 0.000 claims description 13
- 239000003623 enhancer Substances 0.000 claims description 12
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 9
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 208000031220 Hemophilia Diseases 0.000 claims description 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 6
- 208000025678 Ciliary Motility disease Diseases 0.000 claims description 6
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 241000711408 Murine respirovirus Species 0.000 claims description 6
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims description 6
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 108010042653 IgA receptor Proteins 0.000 claims description 5
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims description 5
- 201000003489 pulmonary alveolar proteinosis Diseases 0.000 claims description 5
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 4
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 101710150344 Protein Rev Proteins 0.000 claims description 4
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 3
- 108010023321 Factor VII Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940012413 factor vii Drugs 0.000 claims description 3
- 239000012678 infectious agent Substances 0.000 claims description 3
- 102100032300 Dynein axonemal heavy chain 11 Human genes 0.000 claims description 2
- 102100031648 Dynein axonemal heavy chain 5 Human genes 0.000 claims description 2
- 102100033595 Dynein axonemal intermediate chain 1 Human genes 0.000 claims description 2
- 102100033596 Dynein axonemal intermediate chain 2 Human genes 0.000 claims description 2
- 108010076282 Factor IX Proteins 0.000 claims description 2
- 108010014173 Factor X Proteins 0.000 claims description 2
- 101001016208 Homo sapiens Dynein axonemal heavy chain 11 Proteins 0.000 claims description 2
- 101000866368 Homo sapiens Dynein axonemal heavy chain 5 Proteins 0.000 claims description 2
- 101000872267 Homo sapiens Dynein axonemal intermediate chain 1 Proteins 0.000 claims description 2
- 101000872272 Homo sapiens Dynein axonemal intermediate chain 2 Proteins 0.000 claims description 2
- 241000713325 Visna/maedi virus Species 0.000 claims description 2
- 229960004222 factor ix Drugs 0.000 claims description 2
- 229940012426 factor x Drugs 0.000 claims description 2
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 2
- 102100036537 von Willebrand factor Human genes 0.000 claims description 2
- 229960001134 von willebrand factor Drugs 0.000 claims description 2
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 230000004927 fusion Effects 0.000 abstract description 6
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 175
- 210000004072 lung Anatomy 0.000 description 75
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 61
- 238000010361 transduction Methods 0.000 description 60
- 230000026683 transduction Effects 0.000 description 58
- 241000699670 Mus sp. Species 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 150000007523 nucleic acids Chemical group 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 32
- 108091028043 Nucleic acid sequence Proteins 0.000 description 31
- 239000012530 fluid Substances 0.000 description 31
- 239000005090 green fluorescent protein Substances 0.000 description 29
- 108060001084 Luciferase Proteins 0.000 description 28
- 239000005089 Luciferase Substances 0.000 description 28
- 241000700605 Viruses Species 0.000 description 28
- 238000001727 in vivo Methods 0.000 description 28
- 210000000270 basal cell Anatomy 0.000 description 26
- 239000002609 medium Substances 0.000 description 26
- 238000012546 transfer Methods 0.000 description 26
- 241000701022 Cytomegalovirus Species 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 24
- 239000012634 fragment Substances 0.000 description 23
- 230000007774 longterm Effects 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 210000001331 nose Anatomy 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 16
- 102000040430 polynucleotide Human genes 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 210000002345 respiratory system Anatomy 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 14
- 210000005265 lung cell Anatomy 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 239000013603 viral vector Substances 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000005415 bioluminescence Methods 0.000 description 12
- 230000029918 bioluminescence Effects 0.000 description 12
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 12
- 241000963438 Gaussia <copepod> Species 0.000 description 11
- 108700008625 Reporter Genes Proteins 0.000 description 11
- 239000000443 aerosol Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 210000002919 epithelial cell Anatomy 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- -1 A1AT Proteins 0.000 description 9
- 108010028275 Leukocyte Elastase Proteins 0.000 description 9
- 102000016799 Leukocyte elastase Human genes 0.000 description 9
- 241001494479 Pecora Species 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 210000002850 nasal mucosa Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 210000003463 organelle Anatomy 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 7
- 229920001363 Polidocanol Polymers 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000005058 airway cell Anatomy 0.000 description 7
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 7
- 229960002226 polidocanol Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- 108010061833 Integrases Proteins 0.000 description 6
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 208000014951 hematologic disease Diseases 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 210000003928 nasal cavity Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 201000003542 Factor VIII deficiency Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 101150037996 KRT5 gene Proteins 0.000 description 5
- 108700005077 Viral Genes Proteins 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000002641 enzyme replacement therapy Methods 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 208000027276 Von Willebrand disease Diseases 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 4
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 101150029409 CFTR gene Proteins 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 241000021375 Xenogenes Species 0.000 description 3
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 description 3
- 229940023020 acriflavine Drugs 0.000 description 3
- 210000001552 airway epithelial cell Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 201000007386 factor VII deficiency Diseases 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 210000002220 organoid Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 210000002588 alveolar type II cell Anatomy 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000003011 anion exchange membrane Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000000254 ciliated cell Anatomy 0.000 description 2
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 2
- 210000001100 crypt cell Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 201000007219 factor XI deficiency Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000011140 membrane chromatography Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 210000004412 neuroendocrine cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000001706 olfactory mucosa Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- BULVZWIRKLYCBC-UHFFFAOYSA-N phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 description 2
- 238000012794 pre-harvesting Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000007702 DNA assembly Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150008820 HN gene Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102220470475 L-seryl-tRNA(Sec) kinase_C57L_mutation Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000006416 Notata Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010068733 Respiratory fatigue Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101150037054 aat gene Proteins 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000003050 experimental design method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000537 nasal bone Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000008518 non respiratory effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000005501 phase interface Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18845—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1409089.8A GB2526339A (en) | 2014-05-21 | 2014-05-21 | Lentiviral vectors |
| PCT/GB2015/051201 WO2015177501A1 (en) | 2014-05-21 | 2015-04-23 | Lentiviral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201692361A1 EA201692361A1 (ru) | 2017-05-31 |
| EA038966B1 true EA038966B1 (ru) | 2021-11-16 |
Family
ID=51135270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201692361A EA038966B1 (ru) | 2014-05-21 | 2015-04-23 | Лентивирусный вектор для генной терапии, способ его получения и его применение |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10704061B2 (enExample) |
| EP (1) | EP3145949B1 (enExample) |
| JP (1) | JP6637444B2 (enExample) |
| AU (1) | AU2015263150B2 (enExample) |
| CA (1) | CA2947125C (enExample) |
| CY (1) | CY1123413T1 (enExample) |
| DK (1) | DK3145949T3 (enExample) |
| EA (1) | EA038966B1 (enExample) |
| ES (1) | ES2805045T3 (enExample) |
| GB (1) | GB2526339A (enExample) |
| HR (1) | HRP20200930T1 (enExample) |
| HU (1) | HUE051269T2 (enExample) |
| LT (1) | LT3145949T (enExample) |
| ME (1) | ME03789B (enExample) |
| PL (1) | PL3145949T3 (enExample) |
| PT (1) | PT3145949T (enExample) |
| RS (1) | RS60586B1 (enExample) |
| SI (1) | SI3145949T1 (enExample) |
| SM (1) | SMT202000360T1 (enExample) |
| UA (1) | UA122127C2 (enExample) |
| WO (1) | WO2015177501A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102015012334A2 (pt) * | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
| SI3377637T1 (sl) | 2016-04-08 | 2020-08-31 | Krystal Biotech, Inc. | Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože |
| JP2018174874A (ja) * | 2017-04-19 | 2018-11-15 | 国立大学法人 東京医科歯科大学 | 上皮細胞の水分泌機能測定方法 |
| JP7511469B2 (ja) | 2017-09-27 | 2024-07-05 | イノザイム ファーマ， インコーポレイテッド | 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。 |
| GB201814590D0 (en) * | 2018-09-07 | 2018-10-24 | Oxford Biomedica Ltd | Viral vector production system |
| WO2019200163A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| CN112041434A (zh) | 2018-04-27 | 2020-12-04 | 克里斯托生物技术股份有限公司 | 用于美容性应用的编码一种或多种美容蛋白的重组核酸 |
| CN112384247B (zh) * | 2018-07-02 | 2024-09-27 | 库拉米斯公司 | 利用细胞融合技术的基因及细胞治疗剂以及其的用途 |
| WO2020009444A1 (ko) * | 2018-07-02 | 2020-01-09 | 서울대학교산학협력단 | 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도 |
| CA3112627A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
| MX2021008832A (es) | 2019-02-08 | 2021-09-08 | Krystal Biotech Inc | Composiciones y metodos para la administracion de polipeptidos cftr. |
| BR112021017853A2 (pt) * | 2019-03-13 | 2021-11-30 | Generation Bio Co | Vetores de dna não virais e usos dos mesmos para expressar terapêuticas de fviii |
| CN112575034B (zh) * | 2019-09-29 | 2023-04-25 | 济南赛尔生物科技股份有限公司 | 一种治疗a型血友病的产品及应用 |
| US20210189427A1 (en) * | 2019-12-20 | 2021-06-24 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
| WO2021222222A1 (en) * | 2020-04-27 | 2021-11-04 | Mccray Jr Paul B | Compositions and methods for the treatment of cystic fibrosis |
| US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
| CN116157145A (zh) | 2020-06-09 | 2023-05-23 | 依诺兹梅制药公司 | 可溶性enpp1或enpp3蛋白及其用途 |
| KR20230074703A (ko) * | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| US20230303665A1 (en) | 2020-08-28 | 2023-09-28 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
| MX2023003021A (es) * | 2020-09-16 | 2023-05-24 | Generation Bio Co | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii. |
| GB202100688D0 (en) * | 2021-01-19 | 2021-03-03 | Autolus Ltd | Process |
| GB202102832D0 (en) * | 2021-02-26 | 2021-04-14 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| AU2022246917A1 (en) | 2021-04-02 | 2023-10-12 | Krystal Biotech, Inc. | Viral vectors for cancer therapy |
| GB202105278D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Cell therapy |
| GB202105276D0 (en) * | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Delivery of gene therapy vectors |
| EP4373951A1 (en) * | 2021-07-19 | 2024-05-29 | 2seventy bio, Inc. | Vector manufacturing processes |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| JP2025513059A (ja) | 2022-04-11 | 2025-04-22 | アイピー２アイピーオー イノベーションズ リミテッド | 組合せ治療 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| GB202212472D0 (en) * | 2022-08-26 | 2022-10-12 | Ip2Ipo Innovations Ltd | Retroviral vectors |
| US20260053948A1 (en) | 2022-09-15 | 2026-02-26 | Yeda Research And Development Co. Ltd. | Compositions and methods for virotherapy |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029274A2 (en) * | 2001-09-28 | 2003-04-10 | University Of North Carolina At Chapel Hill | Paramyxoviruses as gene transfer vectors to lung cells |
| WO2007110628A2 (en) * | 2006-03-28 | 2007-10-04 | Isis Innovation Limited | Compositions and methods for therapy of cystic fibrosis |
| EP1950307A1 (en) * | 2005-10-28 | 2008-07-30 | Dnavec Research Inc. | Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1980617A1 (en) * | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| AU2001262684A1 (en) * | 2000-06-01 | 2001-12-11 | Dnavec Research Inc. | Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity |
| CA2462628C (en) * | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| EP1950303A1 (de) | 2007-01-26 | 2008-07-30 | Bayer CropScience AG | Genetisch modifizierte Pflanzen, die eine Stärke mit geringem Amylosegehalt und erhöhtem Quellvermögen synthetisieren |
| HUE030719T2 (en) * | 2007-04-09 | 2017-05-29 | Univ Florida | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
-
2014
- 2014-05-21 GB GB1409089.8A patent/GB2526339A/en not_active Withdrawn
-
2015
- 2015-04-23 EA EA201692361A patent/EA038966B1/ru unknown
- 2015-04-23 WO PCT/GB2015/051201 patent/WO2015177501A1/en not_active Ceased
- 2015-04-23 HU HUE15720762A patent/HUE051269T2/hu unknown
- 2015-04-23 EP EP15720762.2A patent/EP3145949B1/en active Active
- 2015-04-23 AU AU2015263150A patent/AU2015263150B2/en active Active
- 2015-04-23 SM SM20200360T patent/SMT202000360T1/it unknown
- 2015-04-23 JP JP2016567082A patent/JP6637444B2/ja active Active
- 2015-04-23 HR HRP20200930TT patent/HRP20200930T1/hr unknown
- 2015-04-23 SI SI201531275T patent/SI3145949T1/sl unknown
- 2015-04-23 PL PL15720762T patent/PL3145949T3/pl unknown
- 2015-04-23 RS RS20200724A patent/RS60586B1/sr unknown
- 2015-04-23 CA CA2947125A patent/CA2947125C/en active Active
- 2015-04-23 PT PT157207622T patent/PT3145949T/pt unknown
- 2015-04-23 DK DK15720762.2T patent/DK3145949T3/da active
- 2015-04-23 LT LTEP15720762.2T patent/LT3145949T/lt unknown
- 2015-04-23 ES ES15720762T patent/ES2805045T3/es active Active
- 2015-04-23 US US15/312,026 patent/US10704061B2/en active Active
- 2015-04-23 ME MEP-2020-114A patent/ME03789B/me unknown
- 2015-04-23 UA UAA201612986A patent/UA122127C2/uk unknown
-
2020
- 2020-07-03 CY CY20201100617T patent/CY1123413T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029274A2 (en) * | 2001-09-28 | 2003-04-10 | University Of North Carolina At Chapel Hill | Paramyxoviruses as gene transfer vectors to lung cells |
| EP1950307A1 (en) * | 2005-10-28 | 2008-07-30 | Dnavec Research Inc. | Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein |
| WO2007110628A2 (en) * | 2006-03-28 | 2007-10-04 | Isis Innovation Limited | Compositions and methods for therapy of cystic fibrosis |
Non-Patent Citations (7)
| Title |
|---|
| CHUAH M K L, COLLEN D, VANDENDRIESSCHE T: "GENE THERAPY FOR HEMOPHILIA", THE JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 03, no. 01, 1 January 2001 (2001-01-01), US , pages 03 - 20, XP009017044, ISSN: 1099-498X, DOI: 10.1002/1521-2254(200101/02)3:1<3::AID-JGM167>3.0.CO;2-H * |
| DANIELA ZYCHLINSKI, AXEL SCHAMBACH, UTE MODLICH, TOBIAS MAETZIG, JOHANN MEYER, ELKE GRASSMAN, ANJALI MISHRA, CHRISTOPHER BAUM: "Physiological Promoters Reduce the Genotoxic Risk of Integrating Gene Vectors", MOLECULAR THERAPY, NO LONGER PUBLISHED BY ELSEVIER, vol. 16, no. 4, 1 April 2008 (2008-04-01), pages 718 - 725, XP055199418, ISSN: 15250016, DOI: 10.1038/mt.2008.5 * |
| JAMES CRONIN, ZHANG XIAN-YANG, REISER JAKOB: "Altering the Tropism of Lentiviral Vectors through Pseudotyping", CURRENT GENE THERAPY, vol. 5, no. 4, 1 August 2005 (2005-08-01), pages 387 - 398, XP055199682, ISSN: 15665232, DOI: 10.2174/1566523054546224 * |
| JOHN F. ENGELHARDT: "The lung as a metabolic factory for gene therapy", JOURNAL OF CLINICAL INVESTIGATION, vol. 110, no. 4, 15 August 2002 (2002-08-15), pages 429 - 432, XP055199495, ISSN: 00219738, DOI: 10.1172/JCI200216443 * |
| KATSUYUKI MITOMO, GRIESENBACH UTA, INOUE MAKOTO, SOMERTON LUCINDA, MENG CUIXIANG, AKIBA EIJI, TABATA TOSHIAKI, UEDA YASUJI, FRANKE: "Toward Gene Therapy for Cystic Fibrosis Using a Lentivirus Pseudotyped With Sendai Virus Envelopes", MOLECULAR THERAPY, NO LONGER PUBLISHED BY ELSEVIER, vol. 18, no. 6, 1 June 2010 (2010-06-01), pages 1173 - 1182, XP055199531, ISSN: 15250016, DOI: 10.1038/mt.2010.13 * |
| NAKAJIMA T, ET AL.: "DEVELOPMENT OF NOVEL SIMIAN IMMUNODEFICIENCY VIRUS VECTORS CARRYINGA DUAL GENE EXPRESSION SYSTEM", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 11, no. 13, 1 September 2000 (2000-09-01), GB , pages 1863 - 1874, XP001033905, ISSN: 1043-0342, DOI: 10.1089/10430340050129486 * |
| SCOTT R. WITTING, LIN-HONG LI, APARNA JASTI, CORNELL ALLEN, KENNETH CORNETTA, JAMES BRADY, RAMA SHIVAKUMAR, MADHUSUDAN V. PESHWA: "Efficient Large Volume Lentiviral Vector Production Using Flow Electroporation", HUMAN GENE THERAPY, MARY ANN LIEBERT, vol. 23, no. 2, 1 February 2012 (2012-02-01), pages 243 - 249, XP055143670, ISSN: 10430342, DOI: 10.1089/hum.2011.088 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SMT202000360T1 (it) | 2020-09-10 |
| GB2526339A (en) | 2015-11-25 |
| LT3145949T (lt) | 2020-08-25 |
| EP3145949B1 (en) | 2020-04-08 |
| RS60586B1 (sr) | 2020-08-31 |
| CA2947125A1 (en) | 2015-11-26 |
| GB201409089D0 (en) | 2014-07-02 |
| JP6637444B2 (ja) | 2020-01-29 |
| UA122127C2 (uk) | 2020-09-25 |
| HUE051269T2 (hu) | 2021-03-01 |
| PL3145949T3 (pl) | 2021-01-25 |
| CY1123413T1 (el) | 2021-12-31 |
| WO2015177501A1 (en) | 2015-11-26 |
| PT3145949T (pt) | 2020-07-13 |
| DK3145949T3 (da) | 2020-06-29 |
| JP2017521049A (ja) | 2017-08-03 |
| CA2947125C (en) | 2023-02-28 |
| EA201692361A1 (ru) | 2017-05-31 |
| SI3145949T1 (sl) | 2020-08-31 |
| HRP20200930T1 (hr) | 2020-09-18 |
| EP3145949A1 (en) | 2017-03-29 |
| AU2015263150A1 (en) | 2016-11-10 |
| ME03789B (me) | 2021-04-20 |
| US10704061B2 (en) | 2020-07-07 |
| ES2805045T3 (es) | 2021-02-10 |
| AU2015263150B2 (en) | 2020-04-16 |
| US20170096684A1 (en) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10704061B2 (en) | Lentiviral vectors | |
| AU2020260485B2 (en) | Gene therapies for lysosomal disorders | |
| RU2758489C2 (ru) | Композиции и способы для экспрессии нескольких биологически активных полипептидов с одного вектора для лечения заболеваний сердца и других патологий | |
| SA516371030B1 (ar) | نواقل لإظهار مولدات مضاد مصاحبة للبروستاتا | |
| KR20220078607A (ko) | 융합 단백질들을 이용한 tcr 재프로그래밍을 위한 조성물 및 방법들 | |
| US20240082327A1 (en) | Retroviral vectors | |
| TW202233830A (zh) | 使用下一代工程化t細胞療法治療癌症之組合物及方法 | |
| US20250177574A1 (en) | Retroviral vectors | |
| WO2024062259A1 (en) | Retroviral vector comprising rre inserted within an intron | |
| AU2023351435A1 (en) | Gene therapy | |
| HK40048832B (zh) | 用於溶酶体障碍的基因疗法 |